磷酸蛋白酶1基因在恶性肿瘤中的作用及其研究进展  

The role of SPP1 gene in malignant tumors and its research progress

作　　者：李会 于鹏杰[2] 杨捷 骆玉霜[1] LI Hui;YU Pengjie;YANG Jie;LUO Yushuang(Department of Oncology,Qinghai University Affiliated Hospital,Xining,Qinghai 810001,China;Department of Gastroenterology,Qinghai University Affiliated Hospital,Xining,Qinghai 810001,China;Qinghai University School of Clinical Medicine,Qinghai University,Xining,Qinghai 810001,China)

机构地区：[1]青海大学附属医院肿瘤内科,青海西宁810001 [2]青海大学附属医院胃肠外科,青海西宁810001 [3]青海大学临床医学院,青海西宁810001

出　　处：《安徽医药》2025年第1期1-6,共6页Anhui Medical and Pharmaceutical Journal

基　　金：青海省“昆仑英才·高端创新创业人才项目”(青人才字〔2024〕1号);青海大学附属医院中青年科研基金项目(ASRF-2024-YB-05)。

摘　　要：磷酸蛋白酶1(SPP1)是糖蛋白家族成员之一,广泛表达于肺腺癌、胃癌、食管鳞状细胞癌等肿瘤组织,在多种肿瘤中具有生物标志物的特性。SPP1通过与配体相互作用,影响下游信号通路,使肿瘤免疫微环境处于抑制状态,从而介导多种恶性肿瘤生长、浸润和转移;SPP1亦可通过磷脂酰肌醇3-激酶(PI3K)/蛋白激酶B(AKT)信号通路介导卵巢癌、肝细胞癌出现耐药,而研究表明SPP1抑制剂可以逆转肿瘤耐药,减慢肿瘤发展过程。SPP1有希望成为恶性肿瘤潜在的诊断治疗靶点之一,该研究就SPP1基因在恶性肿瘤研究中进展作一综述。Secreted phosphoprotein 1(SPP1),a member of the glycoprotein family,is extensively expressed in lung adenocarcinoma,gastric cancer,esophageal squamous cell carcinoma,and other tumor tissues,and possesses biomarker properties in a multitude of tumors.By interacting with ligands,SPP1 influences the downstream signaling pathway and impedes the tumor immune microenvironment,thereby facilitating the growth,invasion,and metastasis of various malignant tumors.SPP1 is also capable of mediating drug resistance in ovarian cancer and other forms of cancer.Additionally,SPP1 can also mediate drug resistance in ovarian cancer and hepatocellular carcinoma through the phosphoinositol 3-kinase(PI3K)/protein kinase B(AKT)signaling pathway.Studies have demonstrated that SPP1 inhibitors can reverse tumor drug resistance and slow down tumor progression.SPP1 possesses the potential to be among the viable targets for the diagnosis and treatment of malignant tumors.This study reviews the progress of SPP1 gene research in malignant tumors.

关 键 词：骨桥蛋白质 磷酸蛋白酶1 肿瘤 免疫抑制 肿瘤标志物 耐药 

分 类 号：R730.2[医药卫生—肿瘤]